## Investigation of Choice for Lepromatous Leprosy Confirmation **Key Point:** In multibacillary (MB) leprosy with high bacillary load, slit-skin smear examination from multiple sites is the investigation of choice for confirming lepromatous leprosy and quantifying disease burden using the Bacterial Index (BI). ### Slit-Skin Smear: The Gold Standard for Multibacillary Leprosy | Aspect | Details | |--------|----------| | **Technique** | Slit made with scalpel blade; tissue fluid expressed; smear prepared and stained with Ziehl-Neelsen | | **Sites sampled** | Lesions, earlobes, nose (6 sites minimum for BI calculation) | | **Bacillary Index (BI)** | Graded 0–6+ based on number of AFB per field | | **Interpretation in LL** | BI typically 4+ to 6+ (high bacillary load) | | **Sensitivity in MB** | ~90% (very high in lepromatous leprosy) | | **Cost & practicality** | Low-cost, rapid, field-friendly | **High-Yield:** A patient with numerous lesions, no sensory loss, and 4+ AFB on slit-skin smear has **lepromatous leprosy (LL)**. Multiple site sampling quantifies the Bacterial Index, which guides treatment duration and prognosis. ### Why Not Lepromin Test Here? The lepromin test will be **negative** in lepromatous leprosy (weak cell-mediated immunity). While this confirms LL, it does not quantify disease burden. Slit-skin smear is superior for assessing bacillary load and monitoring treatment response. **Clinical Pearl:** The Bacterial Index (BI) is used to: - Confirm multibacillary disease - Guide treatment duration (MB patients require 12 months of multidrug therapy) - Monitor response to therapy (BI should decrease by ~0.5–1 log per year) - Predict relapse risk (higher BI = higher relapse risk if undertreated) **Mnemonic:** **LL = Lots of Lesions + Lots of Bacilli**; **TT = Tiny lesions + Tiny bacilli count**. [cite:Park 26e Ch 8] 
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.